Introduction
The potential of L-3,4-Dihydroxy-6-[18F]fluorophenylalanine ( 18 F-FDOPA) as a tool for managing glioma was first identified by Heiss et al. in 1996 [14] , following a long history of use in Parkinson's Disease. In the light of recent improvements in tracer synthesis [1] , and the likelihood of its increasingly widespread availability, a review of 18 F-FDOPA is necessary. This is also timely, as despite continuing advances in treatment regimes, the prognosis of glioblastoma multiforme (WHO Grade IV gliomas; GBM) remains poor [2] . While the median survival rate now exceeds 12 months, few patients live longer than two years [3] [4] [5] .
While there is evidence that 18 F-FDOPA can provide additional information in detecting gliomas and planning treatment, it is not widely used in either the research or clinical setting.
One reason for this is the complex synthesis process involved. An automated electrophilic approach is available for radiotracer synthesis [6, 7] , however difficulties with handling 18 F in gaseous form as well as a low radiotracer production yield [8, 9] means a two-step electrophillic cpproach remains the most common method for synthesis [10, 11] . While these limitations may lessen the interest in synthesizing this radiotracer, recent developments have seen the introduction of nucleophilic approaches [12, 13] , which produce 18 F in liquid form. Given the complexity of electrophilic 18 F-FDOPA synthesis and the proven track record for 11 C-MET to provide sensitive and specific measurements of glioma volumes, research facilities may opt to investigate cases using 11 C-MET only. However the short half-life of 11 -C means it generally needs to be produced on site. Despite this, the recent
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availability of single-use synthesis cassettes for 18 F-FDOPA could make its use feasible in more centres.
Imaging is critical to the management of glioma for a number of reasons.
Lower grade gliomas, while less aggressive, also have a poor prognosis with survival rates of between 2-5 years [14] . A significant factor in the management of low-grade tumours is the difficulty in predicting their transformation to a higher grade. A recent study showed that transformation of gliomas from low-grade to high-grade after recurrence can occur in 45-74% of cases, depending on the tumour subtype [15] . Recurrence is also of concern, as incidences subsequent to apparently complete regression can occur due to small colonies of residual cells that are capable of causing reemergence [16] . Recurrent lesions can result in extensive, ipsilateral or contralateral spread with severe symptoms and poor prognosis [17] and are often more aggressive than the initial primary lesion at the time of staging.
The biology of recurrent tumour can differ from de-novo glioma due to the selective effect that treatment imposes on the disease, resulting in a phenotypic shift to more aggressive infiltration [18] . Treatment also affects surrounding healthy tissue by ameliorating the some of the symptoms caused by bulk effects, but also by having an inflammatory and necrotic effect [19] . Combined with the differences in management, these factors alter the task of assessing the tumour whether for the purposes of characterising treatment response, planning or prognosis. For instance, in recurrent tumour, pseudo progression must be distinguished from active tumour [20] , and assessing the response of the tumour can be problematic where regions of recurrence surround a large cavity [21] . In contrast for low grade gliomas the radiological findings form a minority of the score obtained during assessment [22] ,
or if planning the resection of high grade tumours using PET the margins of identifiably active tumour can be more critical than say overall dimension [23] . [24] [25] [26] [27] [28] . An advantage of PET is that it directly examines an aspect of cellular metabolism that may be selected beforehand, while MRI is limited to identifying the physical effects of the tumour such as blood brain barrier breakdown or oedema.
While such physical effects are useful they can be a less direct approach for inferring the location and progression of the tumour. 18 F-FDOPA is transported across the BBB by a number of amino acid transporters, which have been shown to be overexpressed in glioma [29] relative to background (healthy) tissue. In non-striatal tissue, 18 F-FDOPA is converted into either The PET radiotracer, 6-[ 18 F]fluoro-dihydroxy-l-phenylalanine ( 18 F-FDOPA) was first synthesised in the 1980's for the purpose of examining Parkinson's disease [31] .
In 1996, a case study by Heiss et al [32] illustrated 18 F-FDOPA as a potential regions where the blood brain barrier (BBB) is disrupted. However, the regions of infiltrating tumour are known to extend well beyond the margins of BBB disruption [33] . Although oedema is visible on a number of MRI sequences by the variations in intensity that it induces, this does not directly identify regions of active tumour [33] .
There is growing evidence that information gained from other modalities may compliment that obtainable from MRI. This is especially true in low-grade and nonenhancing glioma, where blood brain barrier (BBB) breakdown does not necessarily
occur. An advantage of amino acid radiotracers such as 18 F-FDOPA is that they do not require a perturbed BBB, as transport of the tracer across the BBB is facilitated by amino acid transporters. Moreover, PET tracers allow particular aspects of cellular activity to be imaged more directly, as opposed to relying on the physical changes tumour activity induces. There is also a concern in recurrent glioma, where MRI alone cannot always discriminate enhancing tumour from treatment-induced parenchymal injury, so called post-treatment radiation effect [34, 35] . Posttreatment radiation effects include pseudoprogression and radiation necrosis, believed to cause false declaration of treatment failure in up to 50% of cases [36] [37] [38] [39] .
Although the ability of MRI to distinguish between tumour and other tissue biology has been of significant interest [40] [41] [42] 
acquired simultaneously, providing spatially and temporally registered images.
PET/MRI has shown potential in both the clinical and pre-clinical setting for investigating areas of glioma treatment such as new drug development [46] .
<<Location of Figure 1 >>
Comparison with the PET tracers 11 C-MET, 18 F-FDG and 18 F-FLT
Primary glioma
While the modality most widely used in treatment of gliomas is MRI, positron emission tomography (PET) is becoming more common, with the introduction of new radiotracers to compliment information gained from MRI. In the clinical environment, the most widely used radiotracer for imaging glioma is 18 FFluorodeoxyglucose ( 18 F-FDG) and its use in glioma cases was the first oncological application of PET [47] [48] [49] [50] . However, some studies have highlighted the diagnostic limitations of this tracer [51, 52] . Specifically, the high metbolic rate of normal brain tissue results in a high background uptake of the tracer. This increase in background activity limits the contrast between normal brain tissue and lesions, making it difficult to distinguish between normal tissue and possible lesions. This is of special concern in low-grade gliomas, where glucose metabolism has been shown to be similar to that of normal tissue [53, 54] . In addition, inflammatory lesions such as those from infection also have an elevated glucose metabolism, leading to false positives and incorrect diagnosis [55] . To overcome these limitations, studies have been performed to investigate 18 F-FDOPA as a potential alternative to 18 F-FDG in primary and recurrent gliomas.
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Chen et al [53] In addition to 18 F-FDOPA, other amino acid radiotracers have been shown to detect glioma [58] , including the 18 F-FDOPA metabolite, 3-O-methyl-6-18 F-fluoro-Ldopa (OMFD) [59] . A frequently utilized tracer in this research field is 11 C-MET, which has been investigated extensively [5, 60] and is known to be more effective than 11 Cglucose [61] and CT [62, 63] . However, 11 C-MET has the drawback of a short half-life (20.4 minutes), limiting its availability to centers that are in close proximity to a cyclotron. The 110 minute half-life of 18 F radiotracers make them viable in a wider variety of scenarios. Becherer et al [64] investigated this potential in 20 patients, 18
of which were diagnosed with primary glioma. Results showed that the standard
uptake values (SUVs) of 18 F-FDOPA and 11 C-MET 20 minutes post injection showed a significant correlation (P<0.05) and visual inspection revealed almost identical patterns of spatial uptake. Since both tracers are taken up via amino acid channels, this study suggests that there is a significant potential for 18 F-FDOPA imaging of gliomas where 11 C-MET may be difficult to obtain due to its short half-life.
Recurrent glioma
While 18 F-FDG is used extensively in the diagnosis and treatment of both primary and recurrent gliomas, it is also used in conjunction with MRI to detect recurrent disease, which is frequent in glioma. Detection of low-grade gliomas using 18 F-FDG has limitations due to both the low contrast ratio between tumour and normal tissues, and uptake in inflammatory lesions [53] [54] [55] . Not only is this an issue for low-grade recurrent gliomas [52] , but studies suggest that this is also the case in high-grade recurrent gliomas [50, 65] .
As with their findings for primary gliomas, Chen et al [53] and Tripathi et al [54] demonstrated that 18 F-FDOPA also outperforms 18 F-FDG in the detection of recurrence. In similar studies, Jacob et al [57] and Jora et al [56] showed that the performance of 18 
Comparison with SPECT imaging
In addition to MR and PET imaging, SPECT has been investigated for glioma grading [68] [69] [70] , predicting survival [71] and identifying recurrence [72] [73] [74] . In a study by Karunanithi et al [75] , tumour recurrence was assessed by both 18 A C C E P T E D M A N U S C R I P T 
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Using 18 F-FDOPA to predict survival
In addition to 18 F-FDOPA's utility in detecting primary and recurrent tumours, the ability to predict survival would also be of substantial use. Currently, several factors, such as Karnovsky performance status (KPS), age, tumour size, extent of surgery and tumour grade and histology are used in predicting patient survival [76, 77] . Previous studies have shown that 18 F-FDG is also effective in predicting survival in primary and recurrent glioma patients [78, 79] . However, the low specificity of 18 From these studies, there appears to be some evidence that 18 F-FDOPA can assist in tumour grading, though further research is needed before conclusions can be made.
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Using 18 F-FDOPA for neurosurgical and radiotherapy planning
For planning of both resection and radiation therapy, MRI is widely accepted as the gold standard, with T 1 -contrast-enhanced (T 1 -CE) MRI and T 2 /FLAIR imaging sequences utilized. However, ongoing research has shown that MRI has limitations, due to lack of contrast enhancement in tumoural regions [89] , high contrast enhancement in benign tumours and lesions [89] and a lack of discriminability between malignant tissue and oedema on T 2 /FLAIR imaging [90, 91] . The inclusion of an additional imaging modality to compliment information available from MRI has the potential to assist in neurosurgery and radiation therapy planning, improving patient outcomes. Pafundi et al [87] 
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For the treatment of high-grade gliomas with radiotherapy, the margin added to the gross tumour volume, defined on the contrast enhancing MRI, is 1-2cm to account both for occult infiltration and movement between fractions. In the study by Pafundi et al [76] , two patients exhibited high tracer uptake outside the planned tumour volume, suggesting that a 1-2cm expansion does not fully account for infiltration in all cases.
Using 18 F-FDOPA to assess treatment response
PET imaging is also being investigated as a method for identifying tumour response to new treatments. It is well known that vascular endothelial growth factors (VEGF) play a crucial role in modulating angiogenesis and tumorigenesis, with hypoxia being able to stimulate VEGF secretion through activation of hypoxiainducible transcription factors (HIFs) [92] . Since the prognosis of glioma is so poor, anti-angiogenic drugs that target VEGF have been suggested and introduced into the treatment regime [2, [93] [94] [95] [96] [97] [98] [99] [100] . Bevacizumab is one such anti-angiogenic treatment, designed to inhibit vascular growth following radiotherapy. Although this treatment has already been introduced into the clinical environment, evaluation of its effectiveness is still of significance.
In a study by Harris et al [101] , bevacizumab treatment was evaluated in 24 patients with recurrent gliomas using serially acquired 18 F-FDOPA PET, 18 F-FLT PET and MR imaging. Using voxel-wise changes between acquisitions, parametric response maps (PRMs) were generated for both 18 F-FDOPA and 18 F-FLT PET tracers as well as MRI. Scans were acquired before and twice after administration of bevacizumab treatment. Results from the study showed that an increase in tracer
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uptake volume in PRMs was associated with a shortened progression free survival.
However, only a weak correlation was found between PRM and overall survival, suggesting the need for further research.
F-FDOPA imaging could influence treatment pathways
While it is important to assess the ability for new imaging techniques to assist in patient diagnosis and treatment, advances in research are futile if physicians do not adopt them. In a study by Walter et al [102] , the frequency with which 18 F-FDOPA altered the treatment regime was assessed. For 58 patients, pre-PET, early post-PET and late post-PET surveys were conducted. Survey statistics showed that a considerable percentage of treatment paths were altered when 18 F-FDOPA imaging was considered. It was shown that after considering 18 F-FDOPA PET imaging, clinical suspicion of tumour recurrence decreased in 17%, remained the same in 50% and increase in 33% of cases. In addition, survey results showed that 18 F-FDOPA imaging altered the intended treatment path of 41% of patients, i.e., treatment approaches altered from "wait and see" to invasive treatments and vice-versa. Late post-PET surveys showed that these changes to the intended treatment path were carried out in 75% of cases. This illustrated that 18 F-FDOPA has the potential to have a substantial effect on treatment course, with implementation within the clinical environment having the potential to assist in patient treatment regimes.
F-FDOPA as a tool for cross-validation with new modalities
Recently, 18 F-FDOPA PET imaging has been used to evaluate and validate new techniques and research. Numerous studies have investigated the potential for MR imaging indices, such as apparent diffusion coefficient (ADC), for pre-operative
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tumour grading and treatment planning [103] [104] [105] [106] [107] . However, findings from these studies have been mixed. Rose et al [108] investigated the correlation between 18 F-FDOPA standard uptake value ratio (SUVR) and minimum ADC volumes to attempt to understand the relationship. Results from the study showed that there was little relationship between the two modalities, supporting the idea that areas of low ADC may in fact be related to compression from oedema or even ischemia.
Bell et al [109] used 18 F-FDOPA PET imaging to validate a method for generating a probability map and describing tumour cell infiltration, using MRI indices and whole brain tractography. They were able to show that identification of tumour boundaries was more accurate when delineations took into account progression of infiltrative tumour cells along white matter tracts.
F-FDOPA in detection of brain metastases
Additionally, two studies have been performed to investigate 18 quantitative PET measure of maximum lesion to maximum background uptake ratio was found to be the best discriminator, with a ratio threshold of 1.59 yielding a sensitivity and specificity of 90% and 92.3% respectively.
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These two studies suggest that 18 F-FDOPA may also be used to discriminate metastic tumour progression from post-treatment injuries such as radiation necrosis in previously treated patients.
Limitations of 18 F-FDOPA
In addition to the limitations imposed by tracer synthesis, the effect of treatment procedures on 18 F-FDOPA uptake has also been investigated. As part of their study, Ledezma et al [43] highlighted mild 18 F-FDOPA activity along the tumour resection boundary in several cases studied. More recently, Chiaravalloti et al [112] found a relationship between 18 F-FDOPA uptake in patients with suspected tumour recurrence and the delay in PET imaging post radiotherapy. Results showed that uptake decreased with increasing delay over months, suggesting that a high uptake soon after radiotherapy may be treatment related, and as such, care should be taken when assessing patients with suspected tumour recurrence using 18 F-FDOPA PET.
Finally, 18 F-FDOPA is an amino acid tracer that targets dopamine receptors in the brain, resulting in high uptake within the striatum. As such, care should be taken when assessing tumours in near proximity to the striatum, as high uptake in this area may blur the understanding of the tumour boundary. Distinguishing tumour from healthy tissue in these areas probably entails performing a kinetic analysis of the data, and even then partial volume effects will result in some residual imprecision in the definition of the boundary.
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Conclusion
The discovery that 18 Limitations of 18 F-FDOPA also include its high uptake by the basal ganglia.
While this is a key feature in its use within the management of neuro-degenerate diseases, the diagnostic ability of the tracer is limited for tumours adjacent to this region. Hence it is likely to remain complimentary to MRI, the standard modality for imaging glioma patients. 
18
F-FDOPA altered treatment plan in 41% and this change was followed through in 75%.
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